Literature DB >> 24735798

Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin.

J-H Kang1, S A Hassan2, P Zhao1, C H Tsai-Morris1, M L Dufau3.   

Abstract

BACKGROUND: Long-form (LF) homodimers of the human prolactin receptor (PRLR) mediate prolactin's diverse actions. Short form S1b inhibits the LF function through heterodimerization. Reduced S1b/LF-ratio in breast cancer could contribute to tumor development/progression. Current work defines the structural and functional relevance of the D1 domain of S1b on its inhibitory function on prolactin-induced LF function.
METHODS: Studies were conducted using mutagenesis, promoter/signaling analyses, bioluminescence resonance energy transfer (BRET) and molecular modeling approaches.
RESULTS: Mutation of E69 in D1 S1b or adjacent residues at the receptor surface near to the binding pocket (S) causes loss of its inhibitory effect while mutations away from this region (A) or in the D2 domain display inhibitory action as the wild-type. All S1b mutants preserved prolactin-induced Jak2 activation. BRET reveals an increased affinity in D1 mutated S1b (S) homodimers in transfected cells stably expressing LF. In contrast, affinity in S1b homodimers with either D1 (A) or D2 mutations remained unchanged. This favors LF mediated signaling induced by prolactin. Molecular dynamics simulations show that mutations (S) elicit major conformational changes that propagate downward to the D1/D2 interface and change their relative orientation in the dimers.
CONCLUSIONS: These findings demonstrate the essential role of D1 on the S1b structure and its inhibitory action on prolactin-induced LF-mediated function. GENERAL SIGNIFICANCE: Major changes in receptor conformation and dimerization affinity are triggered by single mutations in critical regions of D1. Our structure-function/simulation studies provide a basis for modeling and design of small molecules to enhance inhibition of LF activation for potential use in breast cancer treatment. Published by Elsevier B.V.

Entities:  

Keywords:  Human prolactin receptor; Short and long form; Structure/function; Subdomain D1

Mesh:

Substances:

Year:  2014        PMID: 24735798      PMCID: PMC4061154          DOI: 10.1016/j.bbagen.2014.04.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

1.  Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.

Authors:  Hongzhen Li; Ying Zhang; Andrew Glass; Tobias Zellweger; Edmund Gehan; Lukas Bubendorf; Edward P Gelmann; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Long dynamics simulations of proteins using atomistic force fields and a continuum representation of solvent effects: calculation of structural and dynamic properties.

Authors:  Xianfeng Li; Sergio A Hassan; Ernest L Mehler
Journal:  Proteins       Date:  2005-08-15

3.  Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor.

Authors:  D J Hilton; S S Watowich; L Katz; H F Lodish
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

4.  The human prolactin receptor gene structure and alternative promoter utilization: the generic promoter hPIII and a novel human promoter hP(N).

Authors:  Z Z Hu; L Zhuang; J Meng; M Leondires; M L Dufau
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

5.  Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11.

Authors:  Z Z Hu; J Meng; M L Dufau
Journal:  J Biol Chem       Date:  2001-08-22       Impact factor: 5.157

6.  The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter.

Authors:  J J Berlanga; J P Garcia-Ruiz; M Perrot-Applanat; P A Kelly; M Edery
Journal:  Mol Endocrinol       Date:  1997-09

7.  Complex 5' genomic structure of the human prolactin receptor: multiple alternative exons 1 and promoter utilization.

Authors:  Zhang-Zhi Hu; Li Zhuang; Jianping Meng; Chon-Hwa Tsai-Morris; Maria L Dufau
Journal:  Endocrinology       Date:  2002-06       Impact factor: 4.736

Review 8.  Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.

Authors:  C Bole-Feysot; V Goffin; M Edery; N Binart; P A Kelly
Journal:  Endocr Rev       Date:  1998-06       Impact factor: 19.871

Review 9.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

10.  Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization.

Authors:  Aamer M Qazi; Chon-Hwa Tsai-Morris; Maria L Dufau
Journal:  Mol Endocrinol       Date:  2006-03-23
View more
  5 in total

1.  Expression of long-form prolactin receptor is associated with lower disease-free and overall survival in node-negative breast cancer patients.

Authors:  Doonyapat Sa-Nguanraksa; Kwanlada Mitpakdi; Norasate Samarnthai; Thanawat Thumrongtaradol; Pornchai O-Charoenrat
Journal:  Gland Surg       Date:  2021-01

Review 2.  The brain as a source and a target of prolactin in mammals.

Authors:  Ana R Costa-Brito; Isabel Gonçalves; Cecília R A Santos
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

Review 3.  Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.

Authors:  Raghuveer Kavarthapu; Maria L Dufau
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

4.  Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.

Authors:  Raghuveer Kavarthapu; Maria L Dufau
Journal:  Oncotarget       Date:  2016-10-04

5.  The role of Prolactin/Prolactin Receptor polymorphisms and expression in breast cancer susceptibility and outcome.

Authors:  Doonyapat Sa-Nguanraksa; Cholladda Thasripoo; Norasate Samarnthai; Tanawan Kummalue; Thanawat Thumrongtaradol; Pornchai O-Charoenrat
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.